Rivaroxaban (Xarelto, BAY59-7939) + Recommended VTE pharmacological treatments according to international guidelines

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Deep Vein Thrombosis (DVT)

Conditions

Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)

Trial Timeline

Jun 27, 2014 → Jan 20, 2017

NCT ID

NCT02210819

About Rivaroxaban (Xarelto, BAY59-7939) + Recommended VTE pharmacological treatments according to international guidelines

Rivaroxaban (Xarelto, BAY59-7939) + Recommended VTE pharmacological treatments according to international guidelines is a pre-clinical stage product being developed by Bayer for Deep Vein Thrombosis (DVT). The current trial status is completed. This product is registered under clinical trial identifier NCT02210819. Target conditions include Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02210819	Pre-clinical	Completed	Jun 27, 2014	Jan 20, 2017	Deep Vein Thrombosis (DVT)

Competing Products

20 competing products in Deep Vein Thrombosis (DVT)

See all competitors

Product	Company	Stage	Hype Score
Edoxaban low dose + Edoxaban high dose	Daiichi Sankyo	Phase 1	33
edoxaban tosylate + enoxaparin/unfractionated heparin + warfarin	Daiichi Sankyo	Phase 2	52
Fragmin (dalteparin sodium )	Pfizer	Pre-clinical	22
Fluconazole	Pfizer	Pre-clinical	22
Dalteparin sodium injection + Warfarin	Pfizer	Approved	84
Low Molecular Weight Heparin (dalteparin)	Pfizer	Approved	84
Apixaban + Unfractionated Heparin (UFH) + Warfarin	Pfizer	Phase 3	76
Apixaban	Pfizer	Approved	84
Apixaban	Bristol Myers Squibb	Phase 2	51
Enoxaparin + Placebo + Apixaban + Placebo	Bristol Myers Squibb	Phase 3	76
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	76
Apixaban	Bristol Myers Squibb	Pre-clinical	22
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	76
Enoxaparin	Sanofi	Pre-clinical	22
Clexane	Sanofi	Approved	84
Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin)	Sanofi	Phase 3	76
SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA)	Sanofi	Phase 3	76
Rivaroxaban (Xarelto, BAY59-7939) + Standard of care	Bayer	Pre-clinical	20
Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) + Unfractionated heparin + Warfarin	Bayer	Phase 3	74
Triptorelin Acetate 3.75mg intramuscular injection	Ipsen	Pre-clinical	20

Other Products from Bayer

TelmisartanApproved

Clotrimazole vaginal tablet + FluconazoleApproved

Levitra (Vardenafil, BAY38-9456)Approved

Avelox (Moxifloxacin, BAY12-8039) + Amoxicillin clavulanic acidApproved

Rivaroxaban 20 MG + WarfarinApproved